This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
by Nalak Das
We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.
Philips (PHG) Gains Despite Recall of SENSE XL Torso Coils
by Zacks Equity Research
Philips (PHG) issues an urgent recall of SENSE XL Torso coils (1.5T and 3.0T) due to heating risks during MRI scans.
Here's Why You Should Add DaVita (DVA) to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
Masimo (MASI) Gets Non-Binding Offer for Consumer Business
by Zacks Equity Research
Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
by Zacks Equity Research
IceCure's (ICCM) ProSense cryoablation system demonstrated a 100% complete ablation rate for breast cancer per a study published in "Cancers."
Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?
by Zacks Equity Research
Shares of Baxter (BAX) are showing signs of stability after falling in the first half of 2024. Let's see what is driving investors' sentiment for the company.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Thermo Fisher (TMO) Strategic Buyouts Aid Amid Macro Issues
by Zacks Equity Research
Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.
Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds
by Zacks Equity Research
Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
by Zacks Equity Research
Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
by Zacks Equity Research
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
by Zacks Equity Research
Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes
DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands
by Zacks Equity Research
DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.
Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System
by Zacks Equity Research
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ
by Zacks Equity Research
KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
DexCom's (DXCM) G7 CGM System Now Connects to Apple Watch
by Zacks Equity Research
DexCom (DXCM) announces the direct connectivity of its G7 CGM system to Apple Watch for users in the United States, the UK, and Ireland.
DexCom (DXCM) Declines on Potential Competition for Stelo (revised)
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
DexCom (DXCM) Declines on Potential Competition for Stelo
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
by Zacks Equity Research
Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.